Sustainable success doesn’t just happen. Discover how a rock-solid business plan turns vague goals into clear wins—and why skipping it could stall your company’s future.

On January 28, 2025, the Company received clearance of its IND from the FDA to initiate a first-in-human Phase 1 dose ...

Lululemon sales flagged in the Americas during 2024 and mounting headwinds, most especially in the U.S., challenge growth ...

Deciding to launch your own business is always going to be a big undertaking. But when you’ve been dreaming of having your ...

Ramp explains that some of the most successful business owners know that tax planning is a year-round process, not a one-time ...

Retirement planning through SIPs is an effective way to build wealth. It’s not just about earnings but wise investing. Start early, stay disciplined, and choose the right mutual funds for a secure ...

Trump signed an executive order aimed at eliminating the Department of Education. It's likely to face lawsuits and pushback ...

From Chinese engineers succeeding where Musk failed to global robot wars heating up, here’s a round-up from today’s China coverage.

A federal judge in Michigan on Wednesday refused to dismiss a lawsuit accusing IBM of forcing out a white male consultant in ...

In August, the Intergovernmental Negotiating Committee (INC) will meet in Geneva for what could be the last chance to force a ...

The FDA has completed its review of the investigational new drug application (IND) for PSV359, and issued a "study may proceed” letter in 1Q 2025. Site activation activities are underway, with the ...

InnoCare Pharma (HKEX: 09969; SSE: 688428), a leading biopharmaceutical company focusing on cancer and autoimmune diseases, today announced the 2024 annual results as of 31 December 2024.